North America and Europe Women's Health Market, By Treatment (Drugs and Device), Indication (Cancer, Reproductive Health, Urological Disorders, Hypothyroidism, Post-Menopausal Syndrome, and Others), Delivery Mode (Prescription and Over the Counter), Drug Type (Branded and Generic), Care Type (General Healthcare & Wellness, Pregnancy & Nursing Care, Pelvic & Uterine Healthcare, and Others), End User (Hospitals and Clinics, Gynecology Centers, Homecare Settings, Research Institutes, and Others), Distribution Channel (Direct Tenders, Retail Sales, Online Sales, and Others) - Industry Trends and Forecast to 2031.
North America and Europe Women’s Health Market Analysis and Size
Rising rates of chronic debilitating conditions among women and changing lifestyles & environmental factors impacting health are some of the drivers boosting the demand in the market. Also, the government initiatives to improve overall health and wellbeing is further propelling the market growth. The major restraint which is impacting the market is the adverse effects associated with certain products. The increasing awareness and acceptance of fertility treatments is acting as an opportunity for the market growth. The high maternal mortality and morbidity is acting as challenge for the market growth.
North America and Europe women’s health market is expected to reach USD 16.49 billion by 2031, from USD 9.12 billion in 2023, growing at the CAGR of 8.0% in the forecast period of 2024 to 2031.
|
Report Metric |
Details |
|
Forecast Period |
2024 to 2031 |
|
Base Year |
2023 |
|
Historic Years |
2022 (Customizable to 2016–2021) |
|
Quantitative Units |
Revenue in USD Billion |
|
Segments Covered |
Treatment (Drugs and Device), Indication (Cancer, Reproductive Health, Urological Disorders, Hypothyroidism, Post-Menopausal Syndrome, and Others), Delivery Mode (Prescription and Over the Counter), Drug Type (Branded and Generic), Care Type (General Healthcare & Wellness, Pregnancy & Nursing Care, Pelvic & Uterine Healthcare, and Others), End User (Hospitals and Clinics, Gynecology Centers, Homecare Settings, Research Institutes, and Others), Distribution Channel (Direct Tenders, Retail Sales, Online Sales, and Others) |
|
Countries Covered |
U.S., Canada, Mexico, Germany, France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey, U.K., and Rest of Europe |
|
Market Players Covered |
Lilly, Abbott, Lupin, GSK plc., Novartis AG, AbbVie Inc., Noven Pharmaceuticals, Inc., Vertical Pharmaceuticals, LLC, Veru Inc., and Pfizer Inc. among others |
Market Definition
The area of medicine and healthcare services known as "women's health" is committed towards the particular biological, physiological, and psychological requirements and problems that affect women at all stages of life. It covers a range of topics related to women-specific wellness promotion, gynaecological care, reproductive health, and sexual health. Also, gender-specific health issues related to menstruation, contraception, pregnancy, childbirth, menopause, and diseases such as osteoporosis, endometriosis, breast cancer, and ovarian cancer are covered under women's health. Women's health also places a strong emphasis on screenings, preventative care, and interventions meant to close the gender gaps in healthcare outcomes, access, and quality.
North America and Europe Women’s Health Market Dynamics
This section deals with understanding the market drivers, opportunities, challenges, and restraints. All of this is discussed in detail below:
Drivers
- Rising Rates of Chronic Debilitating Conditions among Women
The ageing population is a major factor contributing to the rising incidence of chronic diseases among women in North America and Europe. Women are more likely than men to experience age-related illnesses such diabetes, osteoporosis, cardiovascular disease, and some types of cancer. The increasing number of women-specific medical conditions is driving up demand for novel diagnostic techniques, therapeutic approaches, and preventive measures that target early identification, efficient treatment, and favorable outcomes. Healthcare providers, pharmaceutical companies, and makers of medical devices are responding to this need by increasing their investments in R&D to better satisfy the changing demands of women. It is done by broadening their product offerings, and improving healthcare delivery models.
Mitigating the impact of chronic diseases on women's health outcomes in North America and Europe requires public health measures that address social determinants of health, improve access to healthcare services, and promote healthy behaviors. Healthcare institutions, legislators, researchers, and communities must work together to address diseases including osteoporosis, endometriosis, breast cancer, and ovarian cancer, which continue to impact women globally. Thus, the rising rates of chronic debilitating conditions among women is a major driver for the market growth.
- Innovative Technologies being Developed as an Aftermath of R&D Activities
The field of women's healthcare is changing as a result of revolutionary developments in medical technology, which are providing innovative solutions to the diagnosis, treatment, and management of a variety of disorders. These developments cover a wide range of technology, such as targeted medicines, minimally invasive surgical methods, precision medicine, and regenerative medicine strategies.
The demand for specialized healthcare services, collaboration between healthcare providers, academics, and technology developers, and investment in infrastructure and workforce development are all being fueled by the acceptance of these new treatments.
The incorporation of digital health technology, including mobile health apps, telemedicine, and remote monitoring, is improving access to care and enabling women to take an active role in healthcare industry. As a result, the women's health market is expanding quickly and innovating throughout North America and Europe. New technologies are facilitating advances in patient outcomes, treatment quality, and the delivery of healthcare as a whole. Thus, the innovative technologies being developed as an aftermath of R&D activities is propelling the market growth.
Opportunity
- Increasing Recognition for Mental Health
Mental health issues, including depression, anxiety, postpartum depression, and eating disorders, disproportionately affect women, often due to a combination of biological, psychological, and social factors. This heightened awareness of mental health challenges has increased demand for innovative therapies, digital mental health tools, and support services tailored specifically to women's unique needs.
Therefore, in response to this demand, companies specializing in women's mental health have an opportunity to develop and offer a range of solutions aimed at improving mental well-being and addressing mental health disorders among women.
Digital mental health tools, and support services tailored to women's specific needs, stakeholders in the market can contribute to improving mental health outcomes and enhancing the quality of life for women across diverse communities. This is done by investing in the development of innovative therapies. The growing recognition of the importance of mental health and well-being among women in North America and Europe presents a significant opportunity for the market growth.
Restraints/Challenges
- Adverse Effects Associated with Certain Products
Concerns regarding the efficacy and safety of a range of products aimed at women's health, such as personal care items, medical devices, and medications, have surfaced in recent years. Consumers, healthcare practitioners, and regulatory organizations are alarmed about the side effects of these products, which include hormone replacement treatment, contraceptive methods, and cosmetic surgeries.
Adverse consequences from drug use on women's health are common, which emphasizes the value of close observation, informed consent, and individualized treatment plans. Healthcare professionals need to carefully weigh the advantages and disadvantages of pharmaceutical therapies, taking into account the patient's preferences as well as their age, medical history, and comorbidities. Thus, the adverse effects associated with certain products is expected to restrain the market growth.
- Environmental Exposure Impacting Reproductive Health
Environmental exposures pose a significant challenge to women's reproductive health in North America and Europe due to industrialization, urbanization, and widespread chemical use in agriculture, manufacturing, and consumer products. Exposure to endocrine-disrupting chemicals (EDCs) such as BPA, phthalates, and pesticides, found in plastics and personal care items, can lead to infertility, menstrual irregularities, and hormonal imbalances. Air pollution from industrial emissions and vehicle exhaust contributes to adverse pregnancy outcomes such as preterm birth and low birth weight. Stakeholders in the women's health market can mitigate risks and safeguard reproductive health for women across diverse communities. It can be done by raising awareness, implementing preventive measures, and advocating for policies to reduce environmental pollution. Environmental exposures impacting reproductive health represent a multifaceted challenge for the market growth.
Recent Developments
- In November 2023, Lupin entered into an exclusive partnership with Amman Pharmaceuticals Industries (Amman Pharma), a prominent pharmaceutical manufacturer with a presence in the MENA region and various global markets. This collaboration involves the marketing and commercialization rights for Ranibizumab, a biosimilar of Lucentis. This strategic partnership allows Lupin to tap into new regions and expand its market presence, ultimately enhancing the company's position in the pharmaceutical industry
- In July 2023, GSK plc. announced that the U.S. Food and Drug Administration (FDA) approved Jemperli (dostarlimab) as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-approved test. This helped the company to expand its product offering
- In August 2022, Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as a once-daily, single-pill therapy for the management of moderate to severe pain associated with endometriosis in premenopausal women. The treatment course may last up to 24 months. This helped the company to expand its product range
- In November 2020, Avion Pharmaceuticals (subsidiary of Alora Pharmaceuticals, LLC), LLC, a specialty pharmaceutical firm, has secured an exclusive license and commercialization agreement with Aspen Pharma USA Inc. and Aspen Global Incorporated. This agreement grants Avion exclusive rights to relaunch Cenestin (synthetic conjugated estrogens, A) tablet, the sole plant-derived blend of nine conjugated estrogens
- In June 2020, AbbVie Inc. in collaboration with Neurocrine Biosciences, Inc., has announced that the U.S. Food and Drug Administration (FDA) has granted approval for ORIAHNN (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules), allowing for a treatment duration of up to 24 months. ORIAHNN marks the inaugural FDA-approved non-surgical, oral treatment option for addressing heavy menstrual bleeding linked to uterine fibroids in pre-menopausal women. This approval expandsthe company’s portfolio of women's health medications and establishes Neurocrine Biosciences as a key player in the field
North America and Europe Women’s Health Market Scope
The North America and Europe women’s health market is categorized into seven notable segments which are based on treatment, indication, delivery mode, drug type, care type, end user, and distribution channel. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Treatment
- Drugs
- Device
On the basis of treatment, the North America and Europe women’s health market is segmented into drugs and device.
Indication
- Cancer
- Reproductive Health
- Urological Disorders
- Hypothyroidism
- Post-Menopausal Syndrome
- Others
On the basis of indication, the North America and Europe women’s health market is segmented into cancer, reproductive health, urological disorders, hypothyroidism, post-menopausal syndrome, and others.
Delivery Mode
- Prescription
- Over the Counter
On the basis of delivery mode, the North America and Europe women’s health market is segmented into prescription and over the counter.
Drug Type
- Branded
- Generic
On the basis of drug type, the North America and Europe women’s health market is segmented into branded and generic.
Care Type
- General Healthcare & Wellness
- Pregnancy & Nursing Care
- Pelvic & Uterine Healthcare
- Others
On the basis of care type, the North America and Europe women’s health market is segmented into general healthcare & wellness, pregnancy & nursing care, pelvic & uterine healthcare, and others.
End User
- Hospitals and Clinics
- Gynecology Centers
- Homecare Settings
- Research Institutes
- Others
On the basis of end user, the North America and Europe women’s health market is segmented into hospitals and clinics, gynecology centers, homecare settings, research institutes, and others.
Distribution Channel
- Direct Tenders
- Retail Sales
- Online Sales
- Others
On the basis of distribution channel, the North America and Europe women’s health market is segmented into direct tenders, retail sales, online sales, and others.
The North America and Europe Women’s Health Market Regional Analysis/Insights
The North America and Europe women’s health market is categorized into seven notable segments which are based on treatment, indication, delivery mode, drug type, care type, end user, and distribution channel.
The countries covered in the market is U.S., Canada, Mexico, Germany, France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey, U.K., and rest of Europe.
North America is expected to dominate the North America and Europe women’s health market as innovative technologies being developed as an aftermath of R&D activities in the region. The U.S. is expected to dominate the North America women’s health market due to the presence of advanced healthcare infrastructure and technological innovation for women’s healthcare sector. Germany is expected to dominate the Europe women’s health market due to their strong presence in international market with extensive distribution network.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data point downstream and upstream value chain analysis, technical trends porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of regional brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
North America and Europe Women’s Health Market Share Analysis
The North America and Europe women’s health market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to the market.
Some of the major market players operating in the North America and Europe women’s health market are Lilly, Abbott, Lupin, GSK plc., Novartis AG, AbbVie Inc., Noven Pharmaceuticals, Inc., Vertical Pharmaceuticals, LLC, Veru Inc., and Pfizer Inc. among others.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 INDUSTRY INSIGHTS
4.3.1 DRUG TREATMENT RATE IN MATURED MARKETS
4.3.2 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
4.3.3 PATIENT FLOW DIAGRAMS
4.3.4 KEY PRICING STRATEGIES
4.3.5 KEY ENROLLMENT STRATEGIES
4.4 PIPELINE ANALYSIS
4.5 PATENT DATA ANALYSIS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISING RATES OF CHRONIC DEBILITATING CONDITIONS AMONG WOMEN
5.1.2 INNOVATIVE TECHNOLOGIES BEING DEVELOPED AS AN AFTERMATH OF R&D ACTIVITIES
5.1.3 GOVERNMENT INITIATIVES TO IMPROVE OVERALL HEALTH AND WELLBEING
5.1.4 CHANGING LIFESTYLES AND ENVIRONMENTAL FACTORS IMPACTING HEALTH
5.2 RESTRAINTS
5.2.1 ADVERSE EFFECTS ASSOCIATED WITH CERTAIN PRODUCTS
5.2.2 STRICT REGULATIONS IMPOSED BY THE REGULATORY AGENCIES
5.3 OPPORTUNITIES
5.3.1 INCREASING RECOGNITION FOR MENTAL HEALTH
5.3.2 GROWING AWARENESS AND ACCEPTANCE OF FERTILITY TREATMENTS
5.3.3 GROWING INCIDENCES OF SEXUALLY TRANSMITTED DISEASES
5.4 CHALLENGES
5.4.1 ENVIRONMENTAL EXPOSURE IMPACTING REPRODUCTIVE HEALTH
5.4.2 HIGH MATERNAL MORTALITY AND MORBIDITY
6 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY TREATMENT
6.1 OVERVIEW
6.2 DRUGS
6.3 DEVICE
7 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY INDICATION
7.1 OVERVIEW
7.2 CANCER
7.3 REPRODUCTIVE HEALTH
7.4 UROLOGICAL DISORDERS
7.5 HYPOTHYROIDISM
7.6 POST-MENOPAUSAL SYNDROME
7.7 OTHERS
8 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY CARE TYPE
8.1 OVERVIEW
8.2 GENERAL HEALTHCARE & WELLNESS
8.3 PREGNANCY & NURSING CARE
8.4 PELVIC & UTERINE HEALTHCARE
8.5 OTHERS
9 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY DRUG TYPE
9.1 OVERVIEW
9.2 BRANDED
9.3 GENERIC
10 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY DELIVERY MODE
10.1 OVERVIEW
10.2 PRESCRIPTION
10.3 OVER THE COUNTER
11 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS AND CLINICS
11.3 GYNECOLOGY CENTERS
11.4 HOMECARE SETTING
11.5 RESEARCH INSTITUTES
11.6 OTHERS
12 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDERS
12.3 RETAIL SALES
12.4 ONLINE SALES
12.5 OTHERS
13 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET, BY REGION
13.1 NORTH AMERICA
13.1.1 U.S.
13.1.2 CANADA
13.1.3 MEXICO
13.2 EUROPE
13.2.1 GERMANY
13.2.2 FRANCE
13.2.3 U.K.
13.2.4 ITALY
13.2.5 RUSSIA
13.2.6 SPAIN
13.2.7 TURKEY
13.2.8 NETHERLANDS
13.2.9 SWITZERLAND
13.2.10 BELGIUM
13.2.11 REST OF EUROPE
14 NORTH AMERICA AND EUROPE WOMEN HEALTH MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
14.2 COMPANY SHARE ANALYSIS: EUROPE
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 ABBOTT
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 PRODUCT PORTFOLIO
16.1.4 RECENT DEVELOPMENT
16.2 ABBVIE INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 PRODUCT PORTFOLIO
16.2.4 RECENT DEVELOPMENT
16.3 GSK PLC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 PRODUCT PORTFOLIO
16.3.4 RECENT DEVELOPMENT
16.4 LILLY
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENT
16.5 LUPIN
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENT
16.6 NOVARTIS AG
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENT
16.7 NOVEN PHARMACEUTICALS, INC.
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 PFIZER INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENT
16.9 VERTICAL PHARMACEUTICALS, LLC
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 VERU INC.
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
List of Table
TABLE 1 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET, DEVICES
TABLE 2 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET, DRUGS
TABLE 3 PATENT DATA (1/4)
TABLE 4 PATENT DATA (2/4)
TABLE 5 PATENT DATA (3/4)
TABLE 6 PATENT DATA (4/4)
TABLE 7 NORTH AMERICA WOMEN’S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 8 EUROPE WOMEN’S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 9 NORTH AMERICA DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 10 EUROPE DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 11 NORTH AMERICA HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 12 EUROPE HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 13 NORTH AMERICA ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 14 EUROPE ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 15 NORTH AMERICA PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 16 EUROPE PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 17 NORTH AMERICA COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION
TABLE 18 EUROPE COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 19 NORTH AMERICA GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 20 EUROPE GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 21 NORTH AMERICA GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 22 EUROPE GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 23 NORTH AMERICA LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 24 EUROPE LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 25 NORTH AMERICA GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 26 EUROPE GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 27 NORTH AMERICA NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 28 EUROPE NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 29 NORTH AMERICA INSULIN-SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 30 EUROPE INSULIN-SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 31 NORTH AMERICA AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 32 EUROPE AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 33 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 34 EUROPE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 35 NORTH AMERICA DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 36 EUROPE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 37 NORTH AMERICA INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 38 EUROPE INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 39 NORTH AMERICA WOMEN’S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 40 EUROPE WOMEN’S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 41 NORTH AMERICA CANCER IN WOMEN’S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 42 EUROPE CANCER IN WOMEN’S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 43 NORTH AMERICA REPRODUCTIVE HEALTH IN WOMEN’S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 44 EUROPE REPRODUCTIVE HEALTH IN WOMEN’S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 45 NORTH AMERICA UROLOGICAL DISORDERS IN WOMEN’S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 46 EUROPE UROLOGICAL DISORDERS IN WOMEN’S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 47 NORTH AMERICA OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 48 EUROPE OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 49 NORTH AMERICA WOMEN’S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 50 EUROPE WOMEN’S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 51 NORTH AMERICA GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 52 EUROPE GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 53 NORTH AMERICA PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 54 EUROPE PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 55 NORTH AMERICA PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 56 EUROPE PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 57 NORTH AMERICA WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 58 EUROPE WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 59 NORTH AMERICA WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 60 EUROPE WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 61 NORTH AMERICA WOMEN’S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 62 EUROPE WOMEN’S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 63 NORTH AMERICA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 64 EUROPE WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 65 NORTH AMERICA WOMEN'S HEALTH MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 66 U.S. WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 67 U.S. DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 68 U.S. HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 69 U.S. ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 70 U.S. PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 71 U.S. COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 72 U.S. GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 73 U.S. GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 74 U.S. LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 75 U.S. GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 76 U.S. NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 77 U.S. INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 78 U.S. AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 79 U.S. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 80 U.S. DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 81 U.S. INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 82 U.S. WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 83 U.S. CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 84 U.S. REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 85 U.S. UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 86 U.S. OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 87 U.S. WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 88 U.S. WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 89 U.S. WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 90 U.S. GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 91 U.S. PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 92 U.S. PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 93 U.S. WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 94 U.S. WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 95 CANADA WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 96 CANADA DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 97 CANADA HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 98 CANADA ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 99 CANADA PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 100 CANADA COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 101 CANADA GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 102 CANADA GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 103 CANADA LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 104 CANADA GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 105 CANADA NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 106 CANADA INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 107 CANADA AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 108 CANADA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 109 CANADA DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 110 CANADA INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 111 CANADA WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 112 CANADA CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 113 CANADA REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 114 CANADA UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 115 CANADA OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 116 CANADA WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 117 CANADA WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 118 CANADA WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 119 CANADA GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 120 CANADA PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 121 CANADA PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 122 CANADA WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 123 CANADA WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 124 MEXICO WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 125 MEXICO DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 126 MEXICO HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 127 MEXICO ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 128 MEXICO PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 129 MEXICO COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 130 MEXICO GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 131 MEXICO GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 132 MEXICO LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 133 MEXICO GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 134 MEXICO NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 135 MEXICO INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 136 MEXICO AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 137 MEXICO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 138 MEXICO DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 139 MEXICO INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 140 MEXICO WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 141 MEXICO CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 142 MEXICO REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 143 MEXICO UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 144 MEXICO OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 145 MEXICO WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 146 MEXICO WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 147 MEXICO WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 148 MEXICO GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 149 MEXICO PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 150 MEXICO PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 151 MEXICO WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 152 MEXICO WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 153 EUROPE WOMEN'S HEALTH MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 154 GERMANY WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 155 GERMANY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 156 GERMANY HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 157 GERMANY ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 158 GERMANY PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 159 GERMANY COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 160 GERMANY GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 161 GERMANY GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 162 GERMANY LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 163 GERMANY GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 164 GERMANY NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 165 GERMANY INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 166 GERMANY AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 167 GERMANY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 168 GERMANY DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 169 GERMANY INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 170 GERMANY WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 171 GERMANY CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 172 GERMANY REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 173 GERMANY UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 174 GERMANY OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 175 GERMANY WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 176 GERMANY WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 177 GERMANY WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 178 GERMANY GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 179 GERMANY PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 180 GERMANY PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 181 GERMANY WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 182 GERMANY WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 183 FRANCE WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 184 FRANCE DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 185 FRANCE HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 186 FRANCE ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 187 FRANCE PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 188 FRANCE COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 189 FRANCE GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 190 FRANCE GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 191 FRANCE LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 192 FRANCE GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 193 FRANCE NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 194 FRANCE INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 195 FRANCE AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 196 FRANCE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 197 FRANCE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 198 FRANCE INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 199 FRANCE WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 200 FRANCE CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 201 FRANCE REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 202 FRANCE UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 203 FRANCE OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 204 FRANCE WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 205 FRANCE WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 206 FRANCE WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 207 FRANCE GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 208 FRANCE PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 209 FRANCE PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 210 FRANCE WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 211 FRANCE WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 212 U.K. WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 213 U.K. DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 214 U.K. HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 215 U.K. ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 216 U.K. PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 217 U.K. COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 218 U.K. GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 219 U.K. GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 220 U.K. LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 221 U.K. GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 222 U.K. NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 223 U.K. INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 224 U.K. AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 225 U.K. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 226 U.K. DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 227 U.K. INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 228 U.K. WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 229 U.K. CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 230 U.K. REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 231 U.K. UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 232 U.K. OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 233 U.K. WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 234 U.K. WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 235 U.K. WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 236 U.K. GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 237 U.K. PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 238 U.K. PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 239 U.K. WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 240 U.K. WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 241 ITALY WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 242 ITALY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 243 ITALY HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 244 ITALY ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 245 ITALY PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 246 ITALY COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 247 ITALY GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 248 ITALY GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 249 ITALY LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 250 ITALY GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 251 ITALY NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 252 ITALY INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 253 ITALY AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 254 ITALY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 255 ITALY DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 256 ITALY INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 257 ITALY WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 258 ITALY CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 259 ITALY REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 260 ITALY UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 261 ITALY OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 262 ITALY WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 263 ITALY WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 264 ITALY WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 265 ITALY GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 266 ITALY PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 267 ITALY PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 268 ITALY WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 269 ITALY WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 270 RUSSIA WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 271 RUSSIA DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 272 RUSSIA HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 273 RUSSIA ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 274 RUSSIA PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 275 RUSSIA COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 276 RUSSIA GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 277 RUSSIA GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 278 RUSSIA LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 279 RUSSIA GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 280 RUSSIA NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 281 RUSSIA INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 282 RUSSIA AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 283 RUSSIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 284 RUSSIA DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 285 RUSSIA INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 286 RUSSIA WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 287 RUSSIA CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 288 RUSSIA REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 289 RUSSIA UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 290 RUSSIA OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 291 RUSSIA WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 292 RUSSIA WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 293 RUSSIA WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 294 RUSSIA GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 295 RUSSIA PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 296 RUSSIA PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 297 RUSSIA WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 298 RUSSIA WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 299 SPAIN WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 300 SPAIN DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 301 SPAIN HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 302 SPAIN ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 303 SPAIN PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 304 SPAIN COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 305 SPAIN GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 306 SPAIN GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 307 SPAIN LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 308 SPAIN GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 309 SPAIN NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 310 SPAIN INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 311 SPAIN AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 312 SPAIN NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 313 SPAIN DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 314 SPAIN INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 315 SPAIN WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 316 SPAIN CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 317 SPAIN REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 318 SPAIN UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 319 SPAIN OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 320 SPAIN WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 321 SPAIN WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 322 SPAIN WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 323 SPAIN GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 324 SPAIN PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 325 SPAIN PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 326 SPAIN WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 327 SPAIN WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 328 TURKEY WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 329 TURKEY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 330 TURKEY HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 331 TURKEY ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 332 TURKEY PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 333 TURKEY COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 334 TURKEY GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 335 TURKEY GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 336 TURKEY LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 337 TURKEY GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 338 TURKEY NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 339 TURKEY INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 340 TURKEY AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 341 TURKEY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 342 TURKEY DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 343 TURKEY INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 344 TURKEY WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 345 TURKEY CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 346 TURKEY REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 347 TURKEY UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 348 TURKEY OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 349 TURKEY WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 350 TURKEY WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 351 TURKEY WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 352 TURKEY GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 353 TURKEY PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 354 TURKEY PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 355 TURKEY WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 356 TURKEY WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 357 NETHERLANDS WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 358 NETHERLANDS DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 359 NETHERLANDS HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 360 NETHERLANDS ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 361 NETHERLANDS PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 362 NETHERLANDS COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 363 NETHERLANDS GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 364 NETHERLANDS GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 365 NETHERLANDS LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 366 NETHERLANDS GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 367 NETHERLANDS NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 368 NETHERLANDS INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 369 NETHERLANDS AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 370 NETHERLANDS NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 371 NETHERLANDS DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 372 NETHERLANDS INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 373 NETHERLANDS WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 374 NETHERLANDS CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 375 NETHERLANDS REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 376 NETHERLANDS UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 377 NETHERLANDS OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 378 NETHERLANDS WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 379 NETHERLANDS WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 380 NETHERLANDS WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 381 NETHERLANDS GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 382 NETHERLANDS PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 383 NETHERLANDS PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 384 NETHERLANDS WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 385 NETHERLANDS WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 386 SWITZERLAND WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 387 SWITZERLAND DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 388 SWITZERLAND HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 389 SWITZERLAND ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 390 SWITZERLAND PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 391 SWITZERLAND COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 392 SWITZERLAND GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 393 SWITZERLAND GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 394 SWITZERLAND LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 395 SWITZERLAND GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 396 SWITZERLAND NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 397 SWITZERLAND INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 398 SWITZERLAND AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 399 SWITZERLAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 400 SWITZERLAND DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 401 SWITZERLAND INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 402 SWITZERLAND WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 403 SWITZERLAND CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 404 SWITZERLAND REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 405 SWITZERLAND UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 406 SWITZERLAND OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 407 SWITZERLAND WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 408 SWITZERLAND WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 409 SWITZERLAND WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 410 SWITZERLAND GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 411 SWITZERLAND PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 412 SWITZERLAND PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 413 SWITZERLAND WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 414 SWITZERLAND WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 415 BELGIUM WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 416 BELGIUM DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 417 BELGIUM HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 418 BELGIUM ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 419 BELGIUM PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 420 BELGIUM COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 421 BELGIUM GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 422 BELGIUM GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 423 BELGIUM LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 424 BELGIUM GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 425 BELGIUM NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 426 BELGIUM INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 427 BELGIUM AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 428 BELGIUM NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 429 BELGIUM DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 430 BELGIUM INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 431 BELGIUM WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 432 BELGIUM CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 433 BELGIUM REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 434 BELGIUM UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 435 BELGIUM OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 436 BELGIUM WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 437 BELGIUM WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 438 BELGIUM WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 439 BELGIUM GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 440 BELGIUM PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 441 BELGIUM PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 442 BELGIUM WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 443 BELGIUM WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 444 REST OF EUROPE WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: SEGMENTATION
FIGURE 11 THE RISING RATES OF CHRONIC DEBILITATING CONDITIONS AMONG WOMEN IS EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET FROM 2024 TO 2031
FIGURE 12 THE TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET IN 2024 AND 2031
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGE OF NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET
FIGURE 14 NORTH AMERICA WOMEN’S HEALTH MARKET: BY TREATMENT, 2023
FIGURE 15 NORTH AMERICA WOMEN’S HEALTH MARKET: BY TREATMENT, 2024-2031 (USD MILLION)
FIGURE 16 NORTH AMERICA WOMEN’S HEALTH MARKET: BY TREATMENT, CAGR (2024-2031)
FIGURE 17 NORTH AMERICA WOMEN’S HEALTH MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 18 EUROPE WOMEN’S HEALTH MARKET: BY TREATMENT, 2023
FIGURE 19 EUROPE WOMEN’S HEALTH MARKET: BY TREATMENT, 2024-2031 (USD MILLION)
FIGURE 20 EUROPE WOMEN’S HEALTH MARKET: BY TREATMENT, CAGR (2024-2031)
FIGURE 21 EUROPE WOMEN’S HEALTH MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 22 NORTH AMERICA WOMEN’S HEALTH MARKET: BY INDICATION, 2023
FIGURE 23 NORTH AMERICA WOMEN’S HEALTH MARKET: BY INDICATION, 2024-2031 (USD MILLION)
FIGURE 24 NORTH AMERICA WOMEN’S HEALTH MARKET: BY INDICATION, CAGR (2024-2031)
FIGURE 25 NORTH AMERICA WOMEN’S HEALTH MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 26 EUROPE WOMEN’S HEALTH MARKET: BY INDICATION, 2023
FIGURE 27 EUROPE WOMEN’S HEALTH MARKET: BY INDICATION, 2024-2031 (USD MILLION)
FIGURE 28 EUROPE WOMEN’S HEALTH MARKET: BY INDICATION, CAGR (2024-2031)
FIGURE 29 EUROPE WOMEN’S HEALTH MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 30 NORTH AMERICA WOMEN’S HEALTH MARKET: BY CARE TYPE, 2023
FIGURE 31 NORTH AMERICA WOMEN’S HEALTH MARKET: BY CARE TYPE, 2024-2031 (USD MILLION)
FIGURE 32 NORTH AMERICA WOMEN’S HEALTH MARKET: BY CARE TYPE, CAGR (2024-2031)
FIGURE 33 NORTH AMERICA WOMEN’S HEALTH MARKET: BY CARE TYPE, LIFELINE CURVE
FIGURE 34 EUROPE WOMEN’S HEALTH MARKET: BY CARE TYPE, 2023
FIGURE 35 EUROPE WOMEN’S HEALTH MARKET: BY CARE TYPE, 2024-2031 (USD MILLION)
FIGURE 36 EUROPE WOMEN’S HEALTH MARKET: BY CARE TYPE, CAGR (2024-2031)
FIGURE 37 EUROPE WOMEN’S HEALTH MARKET: BY CARE TYPE, LIFELINE CURVE
FIGURE 38 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DRUG TYPE, 2023
FIGURE 39 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DRUG TYPE, 2024-2031 (USD MILLION)
FIGURE 40 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 41 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 42 EUROPE WOMEN’S HEALTH MARKET: BY DRUG TYPE, 2023
FIGURE 43 EUROPE WOMEN’S HEALTH MARKET: BY DRUG TYPE, 2024-2031 (USD MILLION)
FIGURE 44 EUROPE WOMEN’S HEALTH MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 45 EUROPE WOMEN’S HEALTH MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 46 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DELIVERY MODE, 2023
FIGURE 47 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DELIVERY MODE, 2024-2031 (USD MILLION)
FIGURE 48 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DELIVERY MODE, CAGR (2024-2031)
FIGURE 49 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DELIVERY MODE, LIFELINE CURVE
FIGURE 50 EUROPE WOMEN’S HEALTH MARKET: BY DELIVERY MODE, 2023
FIGURE 51 EUROPE WOMEN’S HEALTH MARKET: BY DELIVERY MODE, 2024-2031 (USD MILLION)
FIGURE 52 EUROPE WOMEN’S HEALTH MARKET: BY DELIVERY MODE, CAGR (2024-2031)
FIGURE 53 EUROPE WOMEN’S HEALTH MARKET: BY DELIVERY MODE, LIFELINE CURVE
FIGURE 54 NORTH AMERICA WOMEN’S HEALTH MARKET: BY END USER, 2023
FIGURE 55 NORTH AMERICA WOMEN’S HEALTH MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 56 NORTH AMERICA WOMEN’S HEALTH MARKET: BY END USER, CAGR (2024-2031)
FIGURE 57 NORTH AMERICA WOMEN’S HEALTH MARKET: BY END USER, LIFELINE CURVE
FIGURE 58 EUROPE WOMEN’S HEALTH MARKET: BY END USER, 2023
FIGURE 59 EUROPE WOMEN’S HEALTH MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 60 EUROPE WOMEN’S HEALTH MARKET: BY END USER, CAGR (2024-2031)
FIGURE 61 EUROPE WOMEN’S HEALTH MARKET: BY END USER, LIFELINE CURVE
FIGURE 62 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 63 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 64 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 65 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 66 EUROPE WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 67 EUROPE WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 68 EUROPE WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 69 EUROPE WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 70 NORTH AMERICA WOMEN'S HEALTH MARKET: SNAPSHOT (2023)
FIGURE 71 EUROPE WOMEN'S HEALTH MARKET: SNAPSHOT (2023)
FIGURE 72 NORTH AMERICA WOMEN HEALTH MARKET: COMPANY SHARE 2023 (%)
FIGURE 73 EUROPE WOMEN HEALTH MARKET: COMPANY SHARE 2023 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
